Incretin Drug Cancer Risk: Diabetes Drugs in the Incretin Mimetic Class May Cause an Increased Risk of Pancreatic Cancer and Pancreatitis By Incretin Pancreatic Cancer Lawyer and Diabetes Incretin Drug Cancer Lawyer Jason S. Coomer
Diabetes drugs in the incretin mimetic class may cause an increased health risk of pancreatic cancer and pancreatitis. These incretin diabetes drug include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). These drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Many of these incretin diabetes drugs already include a black box warning regarding thyroid cancer risk, but evidence is growing that these drugs may also create an increased risk of pancreatic cancer. People that are taking incretin diabetes drugs including: Januvia, Janument, Victoza, Byetta, Onglyza, Tradjenta, Bydureon, Oseni, and other diabetes drugs should be aware of the cancer health risks. If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and the loved one was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.
For more information on this topic, please feel free to send an e-mail message to Incretin Drug Pancreatic Cancer Lawyer Jason Coomer or use our online form.
FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes
The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics.